You should be glad to learn that we are standing on the verge of a new yet incredible medicine for regeneration, wherein stem cell transplantation is the key! The transplantation of stem cells facilitates the restoration of the functioning of diseased, debilitates and injured organs and tissues. These stem cells are shaped like embryos and can be traced in umbilical cord blood. It was umbilical cord blood which was originally used 18 years ago for treating disorders related to blood and immune system. The past few decades witnessed immense avenues for the use of stem cells in a number of health conditions, anti-aging treatments, and genetic disorders in the wake of a variety of progenitor cells and multipotent stem cells identified in the cord blood. As a matter of fact, the stem cells were essentially found in umbilical cord blood, is currently used for clinical research for different neurological disorders outside the US.
Stem cell research has by and large produced amazingly successful results for treating worst diseases like Alzheimer’s disease, Parkinson’s disease, Stroke, Cerebral Palsy, Traumatic Brain Injury, Heart Diseases, Spinal Cord Injuries, Diabetes, Immune Deficiencies, and Diabetes, on both human and animal bodies.
In the ensuing years, there could be a swift advancement in adult stem cells research but bit slower and less severity in embryonic stem cells. This is because the latter appears to be a technology of the previous century in combination with therapeutic cloning. The history reveals that by the year 2020, we would see ourselves in a position to be able to generate a wide array of tissues with the help of adult stem cells with significant evolution in the building of tissues and its repair.
The future would also unfold some amazing pharmaceutical products that will devoid the method of removing a stem cell from the body, and instead activate bone marrow cells to be transferred to the required body parts seeking repairs. We might also have many biotech companies in the industry in the coming years, having invested massively into embryonic stem cells and worrying over the ethical issues concerning therein, and the fact of overlooking the potentiality of adult stem cell methodology.
The use of embryos for additional cells would remain to be controversial in contrast to the adult tissues or probably the umbilical cord stem cells. This would result in investors willing to lessen down the risks involved in their funded projects and to their organizations through alliances.
In spite of this, we look forward to watching embryonic stem cell research continuing in some countries, with further advancement features added onto it.